| Identification | Back Directory | [Name]
Ethanone, 1-[4-[[[6-(1H-pyrazol-3-yl)-3-pyridinyl]oxy]methyl]-1-piperidinyl]- | [CAS]
2126874-77-7 | [Synonyms]
TP0472993
CYP4A11/CYP4F2-IN-2
Ethanone, 1-[4-[[[6-(1H-pyrazol-3-yl)-3-pyridinyl]oxy]methyl]-1-piperidinyl]- | [Molecular Formula]
C16H20N4O2 | [MOL File]
2126874-77-7.mol | [Molecular Weight]
300.36 |
| Chemical Properties | Back Directory | [Boiling point ]
568.8±40.0 °C(Predicted) | [density ]
1.209±0.06 g/cm3(Predicted) | [solubility ]
DMSO: Sparingly Soluble: 1-10 mg/ml | [form ]
Solid | [pka]
11.75±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
CYP4A11/CYP4F2-IN-2 is a potent and orally active dual inhibitor of cytochrome P450 (CYP) 4A11 and CYP4F2, with IC50s of 140 nM and 40 nM, respectively. CYP4A11/CYP4F2-IN-2 has potential for the research of renal diseases[1]. | [in vivo]
CYP4A11/CYP4F2-IN-2 (compound 11c) (0.03-1 mg/kg; a single p.o.) inhibits renal 20-HETE production of rats in a dose-dependent manner[1].
CYP4A11/CYP4F2-IN-2 (0.5 mg/kg; i.v.) exhibits low CL (1430 mL/h/kg), moderate Vdss(763 mL/kg), and short T1/2 (0.424 h) in mice[1].
CYP4A11/CYP4F2-IN-2 (1 mg/kg; i.v.) exhibits low CL (226 mL/h/kg), moderate Vdss(839 mL/kg), and T1/2 (3.01 h) in SD rats[1].
CYP4A11/CYP4F2-IN-2 (1 mg/kg; p.o.) exhibits Cmax (623 ng/mL), T1/2 (3.03 h), and high bioavailability (97.7%) in SD rats[1]. | [IC 50]
CYP4A11: 140 nM (IC50); CYP4F2: 40 nM (IC50) | [References]
[1] Kawamura M, et, al. Discovery of Novel Pyrazolylpyridine Derivatives for 20-Hydroxyeicosatetraenoic Acid Synthase Inhibitors with Selective CYP4A11/4F2 Inhibition. J Med Chem. 2022 Nov 10;65(21):14599-14613. DOI:10.1021/acs.jmedchem.2c01089 |
|
|